- Home
- PAYS vs NTHI Comparison
PAYS vs NTHI Comparison
Compare PAYS & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAYS | NTHI |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.4M | 243.9M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | PAYS | NTHI |
|---|---|---|
| Price | $3.40 | $9.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.06 | N/A |
| AVG Volume (30 Days) | ★ 381.5K | 69.4K |
| Earning Date | 03-24-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $74,879,428.00 | $59,990.00 |
| Revenue This Year | $41.20 | N/A |
| Revenue Next Year | $20.62 | N/A |
| P/E Ratio | $26.04 | ★ N/A |
| Revenue Growth | ★ 32.61 | N/A |
| 52 Week Low | $1.80 | $3.20 |
| 52 Week High | $8.88 | $25.00 |
Technical Indicators
Market Signals| Indicator | PAYS | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 23.19 | 47.68 |
| Support Level | $3.25 | $9.05 |
| Resistance Level | $3.51 | $11.38 |
| Average True Range (ATR) | 0.21 | 1.19 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 9.21 | 19.05 |
Price Performance
Historical ComparisonAbout PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).